DSIP vs Pinealon
DSIP is delta sleep-inducing peptide, the nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu isolated in 1977 from the cerebral venous blood of rabbits in induced sleep. Nearly five decades later no DSIP gene, precursor protein or receptor has been identified, and its status as an endogenous sleep factor is disputed within the primary literature itself. Pinealon is the synthetic tripeptide Glu-Asp-Arg, one of the ultrashort peptide bioregulators developed at the St Petersburg Institute of Bioregulation and Gerontology, described by its originators as acting epigenetically through direct interaction with DNA and histone proteins rather than through a receptor. The two are paired in commercial material because both are presented as pineal-adjacent compounds connected with sleep and recovery, and because both descend from Soviet and Russian peptide programmes. No published experiment has administered both. One 2026 orthopaedic review tabulates them alongside each other, and outside that single document the two literatures do not intersect at all.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study located in PubMed or Europe PMC has administered DSIP and Pinealon within the same experiment, in any species or model. Searches across trade names, sequence names and the EDR abbreviation returned exactly one publication that engages both, and it dosed neither. Rahman and colleagues published a narrative review of therapeutic peptides in orthopaedics in 2026 that placed epithalon, delta sleep-inducing peptide and pinealon in a single table of recovery-oriented agents, assigning DSIP the descriptors sleep enhancement, hormonal regulation and stress resilience, and Pinealon the descriptors cognitive support, neuroprotection and sleep-wake modulation. Those descriptors summarise claims drawn from the two separate literatures rather than any measurement the authors made, and the review closed by stating that clinical trials for this class of peptides are lacking. Any comparison between the two compounds is therefore indirect, assembled from experiments that used different species, different stress and injury models, different endpoints and different decades of laboratory method.
The publication that covers both
- 01Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, et al. · JAAOS Global Research & Reviews · narrative review of therapeutic peptide classes proposed as adjuncts in orthopaedic injury management
The review grouped epithalon, delta sleep-inducing peptide and pinealon in one table of sleep and recovery agents. DSIP was described as named for its ability to promote slow-wave sleep in rodent studies and as possibly increasing endogenous growth hormone secretion, and Pinealon as a tripeptide thought to influence neuronal metabolism and mitochondrial function in ageing or stressed neural tissue. No experiment was performed, no comparison between the two was drawn, and the authors stated that clinical trials for this class are currently lacking.
Side by side.
| DSIP | Pinealon | |
|---|---|---|
| Evidence maturity | Preclinical only | Preclinical only |
| Studies cited here | 17 | 18 |
| Published 2023 or later | 1 | 3 |
| Newest paper | 2024 | 2024 |
| Sequence and origin | A nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, isolated in 1977 from the cerebral venous blood of rabbits placed in induced sleep. No DSIP gene, precursor protein or receptor has since been identified, so its endogenous status remains unresolved in the primary literature. | A synthetic tripeptide, Glu-Asp-Arg, designed rather than isolated, belonging to a family of ultrashort peptide bioregulators developed at the St Petersburg Institute of Bioregulation and Gerontology. It is not described as an endogenous circulating peptide. |
| Mechanism as described in the literature | No receptor has been identified. Published work describes blood-brain barrier transport, modulation of stress and hypothalamic-pituitary-adrenal responses, changes in antioxidant enzyme gene expression in ageing rodents, and a reported link to slow-wave sleep and sleep-associated growth hormone release in the rat. | The originating group describes nuclear entry and sequence-specific binding to DNA and histone proteins, with molecular docking identifying candidate promoter sites for apoptosis, antioxidant and neuroplasticity genes. The source reviews present this mechanism explicitly as a hypothesis. |
| Size of the evidence base | Seventeen verified publications in the research entry here: eight rodent in vivo studies, seven human studies and two reviews, spread thinly across the period from 1983 to 2024. | Eighteen verified publications: nine in vitro studies, four rodent in vivo studies, four reviews and a single human clinical report. Almost all of it originates from one research group and its close collaborators. |
| Best-characterised finding | A 1988 rat study in Proceedings of the National Academy of Sciences reporting evidence that linked DSIP to slow-wave sleep and sleep-associated growth hormone release. It remains the most frequently cited mechanistic basis for the compound's sleep claims. | A 2011 study in which Pinealon dose-dependently restricted reactive oxygen species accumulation and reduced necrotic cell death in cerebellar granule cells, neutrophils and PC12 cells under oxidative stress, with delayed ERK1/2 activation and cell-cycle modification. |
| Human data | Present but old and inconsistent. A double-blind polysomnographic study in chronic insomnia found weak effects and concluded that short-term treatment was unlikely to be of major therapeutic benefit. A randomised study in patients under isoflurane anaesthesia found reduced delta rhythm and increased bispectral index, the opposite of the predicted direction. | One occupational study in lorry drivers, in which the tripeptide was applied together with a second bioregulator rather than alone and without a placebo arm. No randomised, placebo-controlled trial of the tripeptide by itself has been published. |
| Evidence maturity | Preclinical only. Human work exists but predates modern trial standards, used intravenous administration, and has not been repeated under contemporary methodology. | Preclinical only. The cellular, rodent and gerontological data stand alone, and the central epigenetic mechanism rests on docking simulations and in vitro binding rather than demonstrated target engagement in vivo. |
| Recency of primary research | Occasional primary output continues: rodent stroke and ischaemia-reperfusion studies through 2021 and a 2024 report on a recombinant fusion peptide expressed in Pichia pastoris. Only one publication in the entry is dated 2023 or later. | Comparable. Three publications are dated 2023 or later, the most recent being a 2024 in vitro study of induced neurons transdifferentiated from the fibroblasts of elderly human donors. No new in vivo work has appeared in that window. |
| Basis of most marketing claims | Generalisation from rodent electrophysiology and from small pre-1995 intravenous studies to a route, dose form and population those studies did not test. | Generalisation from cell culture and molecular docking, and from combination studies in which the tripeptide was never given alone, to cognitive and sleep outcomes that have not been measured in a controlled human trial. |
And what it does not.
Nothing in the published record ranks these two peptides against each other, because no experiment has ever run them together. Their separate literatures are alike in one respect and unlike in every other: both are preclinical, both originate largely from a small number of affiliated laboratories, and neither has pharmacokinetic characterisation for the routes in which the compounds are supplied. Beyond that they diverge. DSIP has a genuine human trial record, but it is small, concentrated in the 1980s and early 1990s, produced inconsistent sleep outcomes, and includes a randomised anaesthesia study whose result ran opposite to the sleep hypothesis. Pinealon has almost no human record at all: one occupational study in which it was given in combination with another peptide and without a placebo arm. Its central epigenetic mechanism rests on docking simulations and in vitro binding rather than demonstrated engagement in a living brain. Neither compound has a controlled demonstration of an effect on human sleep architecture, which is the use that prompts the comparison in the first place.
Common questions.
- Has any experiment administered both DSIP and Pinealon to the same animals?
No. Searches of PubMed and Europe PMC across trade names, full sequences and the EDR abbreviation returned no study that dosed both compounds within one design, in any species. The only indexed publication that engages both is a 2026 narrative review of therapeutic peptides in orthopaedics, which listed them in the same table of sleep and recovery agents but performed no experiment and drew no comparison. Every statement setting the two against each other therefore rests on separate studies that differ in species, model, endpoint and era.
- Do the two peptides share a proposed mechanism?
Only loosely, and at the level of antioxidant effects. Rodent work reported that DSIP altered antioxidant enzyme gene expression and reduced markers of oxidative protein modification during ageing, and cell work reported that Pinealon restricted reactive oxygen species accumulation under oxidative stress. Past that point they diverge. DSIP has been studied as a circulating factor with no identified receptor, while Pinealon is described by its originators as acting inside the nucleus on DNA and histone proteins. Neither mechanism has been demonstrated by target engagement in a living human.
- Which of the two has more human data?
DSIP, although the margin says little. Seven human studies appear in its research entry, including double-blind work in chronic insomnia, an open pilot in chronic pain, an open trial in opioid detoxification and a randomised study conducted during isoflurane anaesthesia. The results were inconsistent and most of the work predates 1999. Pinealon has one human report, an occupational study of lorry drivers in which it was applied alongside a second peptide with no placebo group. Neither compound has a modern randomised, placebo-controlled trial.
- Why is the description of DSIP as a sleep factor treated as contested?
Because no DSIP gene, precursor protein or receptor has ever been isolated, and the human measurements do not behave as the hypothesis predicts. A diurnal sampling study reported that plasma DSIP correlated positively with body temperature and negatively with rapid eye movement and slow-wave sleep, the reverse of the pattern expected of a circulating slow-wave-sleep-promoting factor. A 2006 critical review in the Journal of Neurochemistry concluded that the sleep-factor hypothesis was poorly documented and weak.
- How much of each evidence base is independent of the group that developed the compound?
Very little for Pinealon. Its in vitro, rodent and human work comes almost entirely from the St Petersburg Institute of Bioregulation and Gerontology and its collaborators, and independent replication outside that group is effectively absent. DSIP is somewhat broader, with contributions from Swiss, Dutch, German, American, Indian and Russian laboratories across five decades, but no individual finding has a strong independent replication record, and recent primary work is again concentrated in a small number of Russian groups.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.